Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2014

View Archived Issues

Novel genetic variants associated with susceptibility to anorexia nervosa

Novel biological candidate SM-101 shows promise in phase II trials in patient with SLE

FDA grants imiquimod orphan status for carcinoma in situ of the urinary bladder

Liposome encapsulated paclitaxel receives U.S. orphan designation for gastric cancer

Neurocrine Biosciences begins phase I/II trial of NBI-77860

Nihon Medi-Physics patents Abeta imaging agents

International PANACEA study opens in patients with HER2+ breast cancer

Phase II data for sotatercept as treatment of anemia in hemodialysis subjects

PF-06747143: a novel CXCR4 antagonist antibody for the treatment of hematological malignancies

Clinical studies of lucitanib in breast cancer

Karyopharm begins third registration-directed trial of selinexor

Taiho Pharmaceutical divulges PKB inhibitors

Oral Health Australia reports propeptides for periodontal diseases

Novel vinca alkaloids presented by Gedeon Richter

Noribogaine HCl safe and well tolerated in healthy volunteers

Plexxikon and QuantumLeap select PLX-3397 for I-SPY 2 TRIAL in breast cancer

FDA accepts IND application for AGT-182 for the treatment of Hunter syndrome

Pieris begins phase I study of Anticalin to treat anemia

NIHR confirms start of study to test new drug for Sjogren's syndrome

CardioKinetix signs agreement with Edwards Lifesciences

FDA grants conditional approval to Cytori Cell Therapy for trial in scleroderma

FDA approves Quidel's AmpliVue Bordetella Assay

Navidea establishes Macrophage Therapeutics to develop drugs targeting activated macrophages

Lakewood-Amedex submits IND application for phase I/II trial of Nu-3 in diabetic foot ulcer

FDA approves MP Biomedicals' test to confirm HTLV-I/II antibodies

Geneva team pauses VSV-ZEBOV vaccinations following cases of joint pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...